

Agostino Tafuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1394927/publications.pdf>

Version: 2024-02-01

195
papers

11,997
citations

66234

42
h-index

26548

107
g-index

200
all docs

200
docs citations

200
times ranked

16594
citing authors

#	ARTICLE	IF	CITATIONS
1	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1263-1284.	1.9	1,858
2	Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid). <i>New England Journal of Medicine</i> , 1991, 324, 1385-1393.	13.9	1,226
3	ICOS is essential for effective T-helper-cell responses. <i>Nature</i> , 2001, 409, 105-109.	13.7	629
4	T Cell Awareness of Paternal Alloantigens During Pregnancy. <i>Science</i> , 1995, 270, 630-633.	6.0	524
5	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	1.4	520
6	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	0.8	509
7	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
8	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. <i>Blood</i> , 2007, 110, 840-846.	0.6	419
9	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. <i>Leukemia</i> , 2008, 22, 686-707.	3.3	337
10	Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 4481-4486.	3.3	287
11	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	0.8	279
12	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 781-794.	5.1	254
13	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	0.8	244
14	Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 1995-1999.	0.6	225
15	Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. <i>Leukemia</i> , 2008, 22, 708-722.	3.3	222
16	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
17	Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. <i>Blood</i> , 1991, 77, 700-711.	0.6	183
18	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.	0.6	178

#	ARTICLE	IF	CITATIONS
19	Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. <i>Leukemia</i> , 2009, 23, 25-42.	3.3	174
20	Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. <i>Blood</i> , 2015, 126, 1925-1929.	0.6	154
21	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	0.6	148
22	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. <i>Leukemia</i> , 2012, 26, 778-787.	3.3	126
23	Control of Neonatal Tolerance to Tissue Antigens by Peripheral T Cell Trafficking. , 1998, 282, 1338-1341.		119
24	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.	0.6	109
25	Cycling Status of CD34+ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 1189-1196.	0.6	106
26	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 974-981.	0.6	99
27	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. <i>Neoplasia</i> , 2009, 11, 720-W6.	2.3	87
28	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , 2007, 10, 81-100.	6.5	74
29	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
30	Epidermolysis bullosa and embryonic lethality in mice lacking the multi-PDZ domain protein GRIP1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6816-6821.	3.3	63
31	E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. <i>British Journal of Haematology</i> , 2003, 120, 484-487.	1.2	63
32	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 ^{hi} cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009, 114, 5191-5200.	0.6	62
33	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
34	Emerging MEK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 203-223.	1.0	54
35	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	1.7	54
36	Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg TM CMA-676). <i>British Journal of Haematology</i> , 2001, 115, 63-65.	1.2	53

#	ARTICLE	IF	CITATIONS
37	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. <i>Blood</i> , 2012, 119, 217-226.	0.6	52
38	Histopathological and molecular features of persistent polyclonal B α cell lymphocytosis (PPBL) with progressive splenomegaly. <i>British Journal of Haematology</i> , 2009, 144, 726-731.	1.2	51
39	Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. <i>Blood</i> , 2006, 107, 3495-3502.	0.6	50
40	Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 614-30.	2.3	50
41	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. <i>Oncotarget</i> , 2017, 8, 49451-49469.	0.8	49
42	Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects. <i>Current Pharmaceutical Design</i> , 2005, 11, 2779-2795.	0.9	48
43	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.	0.6	46
44	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	0.8	41
45	MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. <i>Blood</i> , 2007, 109, 2121-2129.	0.6	38
46	Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. <i>Scientific Reports</i> , 2017, 7, 13663.	1.6	38
47	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.	0.8	36
48	Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2002, 16, 2055-2061.	3.3	35
49	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for α vertical α and α lateral α combination strategies. <i>Journal of Molecular Medicine</i> , 2012, 90, 1133-1144.	1.7	35
50	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFN γ -Dendritic Cells and Rituximab: a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5231-5241.	3.2	34
51	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , 2016, 22, 2358-2388.	0.9	34
52	Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. <i>Molecular Pharmacology</i> , 2008, 74, 884-895.	1.0	33
53	Emerging Raf inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 633-648.	1.0	33
54	Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. <i>Advances in Biological Regulation</i> , 2017, 65, 36-58.	1.4	33

#	ARTICLE	IF	CITATIONS
55	Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. <i>Leukemia Research</i> , 1995, 19, 927-931.	0.4	32
56	Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded <i>in vitro</i> from normal donors and from patients with polycythemia vera. <i>American Journal of Hematology</i> , 2013, 88, 723-729.	2.0	32
57	PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. <i>Oncotarget</i> , 2015, 6, 15008-15021.	0.8	32
58	Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. <i>Blood</i> , 1996, 87, 3852-3859.	0.6	31
59	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019, 134, 229-229.	0.6	30
60	The Activity of Differentiation Factors Induces Apoptosis in Polyomavirus Large T-Expressing Myoblasts. <i>Molecular Biology of the Cell</i> , 1998, 9, 1449-1463.	0.9	29
61	t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 788-793.	1.2	28
62	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 18137.	1.6	28
63	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.	2.8	28
64	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
65	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 391-399.	1.2	26
66	An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. <i>Annals of Hematology</i> , 2015, 94, 771-777.	0.8	25
67	Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 705-714.	1.5	25
68	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. <i>Experimental Hematology</i> , 2015, 43, 974-985.e1.	0.2	24
69	Biological Aspects of mTOR in Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2396.	1.8	24
70	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012, 11, 4447-4461.	1.3	22
71	Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside. <i>Hamatologie Und Bluttransfusion</i> , 1990, 33, 747-762.	0.0	22
72	Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. <i>British Journal of Haematology</i> , 1999, 106, 133-141.	1.2	21

#	ARTICLE	IF	CITATIONS
73	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasana) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. <i>Blood</i> , 2018, 132, 767-767.	0.6	21
74	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008, 48, 113-135.	2.9	20
75	Tramesan, a novel polysaccharide from <i>Trametes versicolor</i> . Structural characterization and biological effects. <i>PLoS ONE</i> , 2017, 12, e0171412.	1.1	20
76	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
77	Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1. <i>Annals of Hematology</i> , 1999, 78, 13-18.	0.8	19
78	Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. <i>Blood</i> , 2009, 113, 1522-1525.	0.6	19
79	Metabolic Reprogramming Promotes Myogenesis During Aging. <i>Frontiers in Physiology</i> , 2019, 10, 897.	1.3	19
80	DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. <i>Cancer</i> , 1991, 67, 449-454.	2.0	18
81	Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. <i>Leukemia</i> , 1999, 13, 514-517.	3.3	17
82	Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 1263-1272.	0.9	17
83	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , 2017, 8, 76525-76557.	0.8	17
84	Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. <i>Experimental Hematology</i> , 1999, 27, 1255-1263.	0.2	16
85	Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. <i>Annals of Hematology</i> , 2001, 80, 614-616.	0.8	16
86	SIRT5 Inhibition Induces Brown Fat-Like Phenotype in 3T3-L1 Preadipocytes. <i>Cells</i> , 2021, 10, 1126.	1.8	16
87	Hyperspectral Raman imaging of human prostatic cells: An attempt to differentiate normal and malignant cell lines by univariate and multivariate data analysis. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2017, 173, 476-488.	2.0	15
88	A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. <i>BMC Cancer</i> , 2019, 19, 50.	1.1	15
89	Interleukin-11 induces proliferation of human T-cells and its activity is associated with downregulation of p27(kip1). <i>Haematologica</i> , 2002, 87, 373-80.	1.7	14
90	Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-8.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies. <i>Journal of Translational Medicine</i> , 2021, 19, 139.	1.8	13
92	Effects of IL-6 Variants in Multiple Myeloma: Growth Inhibition and Induction of Apoptosis in Primary Cells. <i>Leukemia and Lymphoma</i> , 2002, 43, 2369-2375.	0.6	12
93	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34 ⁺ human stem cells. <i>British Journal of Haematology</i> , 2003, 123, 720-729.	1.2	12
94	The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. <i>Experimental Hematology</i> , 2017, 50, 53-76.	0.2	12
95	High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. <i>Annals of Hematology</i> , 2003, 82, 476-480.	0.8	11
96	Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation. <i>Leukemia Research</i> , 2006, 30, 785-794.	0.4	11
97	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 548-558.	1.2	10
98	mTOR Regulation of Metabolism in Hematologic Malignancies. <i>Cells</i> , 2020, 9, 404.	1.8	10
99	Hypoxia-inducible factor-1 α (Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors. <i>Blood Transfusion</i> , 2013, 11, 553-7.	0.3	10
100	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	0.8	10
101	High stimulatory activity of dendritic cells from diabetes-prone BioBreeding/Worcester rats exposed to macrophage-derived factors.. <i>Journal of Clinical Investigation</i> , 1993, 91, 2040-2048.	3.9	9
102	Interleukin-9 in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 563-573.	0.6	8
103	Myeloperoxidase gene expression in non-infant pro-B acute lymphoblastic leukaemia with or without ALL1/AF4 transcript. <i>British Journal of Haematology</i> , 2000, 111, 1065-1070.	1.2	8
104	Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 69-72.	1.0	7
105	Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit. <i>British Journal of Haematology</i> , 2018, 183, 819-822.	1.2	7
106	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.	1.2	7
107	Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015, 56, 2206-2207.	0.6	6
108	Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors. <i>Frontiers in Oncology</i> , 2019, 9, 1245.	1.3	6

#	ARTICLE	IF	CITATIONS
109	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	0.8	6
110	Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. <i>Medical and Pediatric Oncology</i> , 1992, 20, 18-22.	1.0	5
111	Interleukin-3 priming in acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 1995, 91, 234-244.	1.2	5
112	Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis. <i>Infection</i> , 2013, 41, 255-258.	2.3	5
113	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <i>Frontiers in Oncology</i> , 2020, 10, 848.	1.3	5
114	Successful Treatment of a Patient With Breast Implant-Associated Anaplastic Large Cell Lymphoma With Local Residual Disease. <i>Annals of Plastic Surgery</i> , 2021, Publish Ahead of Print, .	0.5	5
115	Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia The gimema experience. <i>Experimental Hematology</i> , 2000, 28, 1501-1502.	0.2	4
116	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways. <i>Blood</i> , 2008, 112, 5161-5161.	0.6	4
117	Isolated molecular relapse in FIP1L1-PDGFR α hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1161-1163.	1.1	3
118	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046.	0.5	3
119	Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib. <i>Experimental Hematology and Oncology</i> , 2018, 7, 2.	2.0	3
120	Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 268-271.	1.3	3
121	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1113-1118.	2.0	3
122	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018, 9, 21758-21769.	0.8	3
123	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.	2.7	3
124	Combination Treatment of Acute Myeloblastic Leukemia with rhGM-CSF and Standard Induction Chemotherapy. <i>Cancer Investigation</i> , 1993, 11, 229-234.	0.6	2
125	Effects of mast cell growth factor on ara-c mediated acute myeloid leukemia cell killing. <i>Stem Cells</i> , 1993, 11, 88-92.	1.4	2
126	Thrombopoietin, Interleukin-11, and Early-Acting Megakaryocyte Growth Factors in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 2000, 40, 179-190.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Apoptosis Susceptibility and Cell-Cycle Distribution in Cells from Myelodysplastic Syndrome Patients: Modulatory In-Vitro Effects of G-CSF and Interferon- γ . <i>Leukemia and Lymphoma</i> , 2004, 45, 1437-1443.	0.6	2
128	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018, 69, 18-23.	0.4	2
129	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	0.7	2
130	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	0.8	2
131	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020, 136, 43-44.	0.6	2
132	Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.. <i>Blood</i> , 2007, 110, 2802-2802.	0.6	2
133	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
134	Diagnostic Value of Minor Salivary Glands Biopsy in Systemic Amyloidosis. <i>Blood</i> , 2015, 126, 5381-5381.	0.6	2
135	Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. <i>Annals of Hematology</i> , 2022, 101, 1275-1282.	0.8	2
136	Aberrant Proliferative and Apoptotic Pathways in Acute Lymphoblastic Leukemia (ALL): Molecular Therapies to Overcome Chemo-Resistance. , 2011, , .		1
137	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
138	Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study. <i>In Vivo</i> , 2020, 34, 1407-1413.	0.6	1
139	Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e344-e351.	0.8	1
140	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. <i>Blood</i> , 2007, 110, 3470-3470.	0.6	1
141	Exclusion Criteria In The Dasison and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a "Real-life" Patient Population With Chronic Myelogenous Leukemia?. <i>Blood</i> , 2013, 122, 4002-4002.	0.6	1
142	The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.. <i>Blood</i> , 2007, 110, 155-155.	0.6	1
143	The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.. <i>Blood</i> , 2007, 110, 3344-3344.	0.6	1
144	Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008, 112, 860-860.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3228-3228.	0.6	1
146	MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients., Blood, 2011, 118, 3793-3793.	0.6	1
147	Targeting Metabolic Pathways for Leukemia Treatment. Blood, 2012, 120, 1371-1371.	0.6	1
148	Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 1991, 77, 700-711.	0.6	1
149	Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. Blood, 2015, 126, 2821-2821.	0.6	1
150	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. Blood, 2016, 128, 5544-5544.	0.6	1
151	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). Blood, 2016, 128, 5465-5465.	0.6	1
152	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. Blood, 2019, 134, 3845-3845.	0.6	1
153	CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. Blood, 2021, 138, 1262-1262.	0.6	1
154	Chronic Lymphocytic Leukemia Cells with Mutated Nfkbie Are Positively Selected By Microenvironmental Signals and Display Reduced Sensitivity to Ibrutinib Treatment. Blood, 2021, 138, 248-248.	0.6	1
155	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	0.6	1
156	Sequential Pilot Studies of Intensive Postremission Chemotherapy for Acute Nonlymphocytic Leukemia. Annals of the New York Academy of Sciences, 1987, 511, 436-441.	1.8	0
157	Sexual function with and without erythropoietin therapy. International Journal of Artificial Organs, 1992, 15, 440-441.	0.7	0
158	Cell Kinetic, Molecular and Clinical Analysis of Growth Factor Sensitization of Myeloid Leukemia1. , 1994, , 112-136.		0
159	SP253A NEW STRATEGY TO REMOVE SERUM FREE LIGHT CHAINS(SFLC)IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND ACUTE KIDNEY INJURY (AKI). Nephrology Dialysis Transplantation, 2015, 30, iii462-iii462.	0.4	0
160	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. American Journal of Hematology, 2015, 90, E95-E96.	2.0	0
161	Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse Large B-Cell Lymphoma with Cardiac Involvement. Hemato, 2021, 2, 353-357.	0.2	0
162	Breast Cancer Resistance Protein (BCRP) in Adult Acute Lymphoblastic Leukemia Patients.. Blood, 2004, 104, 1897-1897.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Diagnostic Approach to CD5+/CD23+ Leukemic Non-Hodgkin Lymphomas Lacking Lymphnode Histopathology.. Blood, 2005, 106, 4690-4690.	0.6	0
164	Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.. Blood, 2006, 108, 254-254.	0.6	0
165	Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.. Blood, 2006, 108, 1843-1843.	0.6	0
166	Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.. Blood, 2006, 108, 4612-4612.	0.6	0
167	Lympho Node Enlargement in Adultâ€™s Patients Referred to Hematologist: A Frequent Not Classified Clinical Problem. Results from a Retrospective Study.. Blood, 2006, 108, 2486-2486.	0.6	0
168	JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. Blood, 2007, 110, 4652-4652.	0.6	0
169	Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.. Blood, 2007, 110, 4782-4782.	0.6	0
170	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.. Blood, 2007, 110, 641-641.	0.6	0
171	Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. Blood, 2009, 114, 594-594.	0.6	0
172	Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.. Blood, 2009, 114, 985-985.	0.6	0
173	Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression.. Journal of Clinical Oncology, 2010, 28, 8574-8574.	0.8	0
174	A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. Blood, 2010, 116, 5065-5065.	0.6	0
175	Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,. Blood, 2011, 118, 3581-3581.	0.6	0
176	Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. Blood, 2011, 118, 5157-5157.	0.6	0
177	Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. Blood, 2011, 118, 5172-5172.	0.6	0
178	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3733-3733.	0.6	0
179	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. Blood, 2012, 120, 5062-5062.	0.6	0
180	Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. Blood, 2012, 120, 3769-3769.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Transcriptosome and Phospho-Proteomic Analyses of Erythroblasts Expanded in Vitro From Normal Donors (ND) and From Patients with Polycythemia Vera (PV).. Blood, 2012, 120, 2860-2860.	0.6	0
182	Differential Modulation Of cKIT Signaling By CD63 Dictates The Magnitude Of Response To Stem Cell Factor Of Erythroblasts From Adult Blood, Cord Blood and Polycythemia Vera. Blood, 2013, 122, 2850-2850.	0.6	0
183	Modulation Of The Glycolytic Metabolism In Acute Myeloid Leukemia Cells. Blood, 2013, 122, 5045-5045.	0.6	0
184	Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors. Blood, 2013, 122, 2712-2712.	0.6	0
185	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. Blood, 2014, 124, 3265-3265.	0.6	0
186	The JAK2 V617F Mutation Disrupts the Regulatory Activity Exerted By Calreticulin on the Glucocorticoid Receptor in Erythroid Cells. Blood, 2015, 126, 5216-5216.	0.6	0
187	Targeting Glycolysis and MAPK Pathway: A Combined Pre-Clinical Approach on Acute Myeloid Leukemia. Blood, 2016, 128, 2751-2751.	0.6	0
188	Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients. Blood, 2016, 128, 399-399.	0.6	0
189	The Carboxy-Terminal Domain of Calreticulin (CALR) Exports the Glucocorticoid Receptor (GR) from the Nucleus to the Cytoplasm of Human Erythroid Cells Resetting Their Stress Response. Blood, 2016, 128, 545-545.	0.6	0
190	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. Blood, 2016, 128, 5469-5469.	0.6	0
191	DEVEC metronomic schedule for aggressive B and T-cell lymphomas.. Journal of Clinical Oncology, 2018, 36, 7563-7563.	0.8	0
192	Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region. Blood, 2018, 132, 5550-5550.	0.6	0
193	High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN- α -Dendritic-Cell and Rituximab. Blood, 2018, 132, 5334-5334.	0.6	0
194	Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas. Hematological Oncology, 2023, 41, 571-573.	0.8	0
195	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical "Biological Entity?". Journal of Clinical Medicine, 2022, 11, 2596.	1.0	0